NCT04389840 - Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 8, 2020

Primary Completion Date

May 20, 2021

Study Completion Date

May 20, 2021

Conditions

Coronavirus Disease 2019 (COVID-19)Acute Lung InjurySevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Interventions

DRUG

Dociparstat sodium

Dociparstat is a glycosaminoglycan derived from porcine heparin.

DRUG

Placebo

0.9% Normal Saline

Trial Locations (12)

Wake Forest Baptist Health, Winston-Salem

Augusta University, Augusta

Advanced Pulmonary Research Institute/Wellington Regional Medical Center, Loxahatchee Groves

University of Alabama at Birmingham, Birmingham

Ascension Macomb-Oakland Cardiovascular Research, Warren

William Beaumont Hospital, Royal Oak

Ascension St. Francis Hospital, Milwaukee

Ascension All Saints Hospital, Racine

Tulane University, New Orleans

University Medical Center, New Orleans

Our Lady of the Lake, Baton Rouge

Texas Health Harris Methodist Hospital Fort Worth, Dallas